nafamostat has been researched along with Blood Platelet Disorders in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Blood Platelet Disorders: Disorders caused by abnormalities in platelet count or function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogata, H | 1 |
| Kinugasa, E | 1 |
1 review available for nafamostat and Blood Platelet Disorders
| Article | Year |
|---|---|
[Treatment of uremic patients with high bleeding risk].
Topics: Anticoagulants; Benzamidines; Blood Platelet Disorders; Guanidines; Hemorrhage; Heparin, Low-Molecul | 2004 |